Volume 5 Issue 4 - International Pharmaceutical Industry

Current Edition

Labs and Logistics V5 I4

Uncovering the Temperature-Sensitive Cargo Debate

New and updated Good Distribution Practice (GDP) requirements demand that the pharmaceutical industry sits up and takes notice of the importance of a quality assured...

8 January 2014 Labs and Logistics V5 I4 | Volume 5 Issue 4

Continue Reading →

Labs and Logistics V5 I4

The Right Specification for the Laboratory

Specification and maintenance are important factors to consider when specifying a centralized reverse osmosis (RO) water purification system. Choosing, operating and...

8 January 2014 Labs and Logistics V5 I4 | Volume 5 Issue 4

Continue Reading →

Clinical Research V5 I4

Hyaluronic Acid – Creation of Slow Release Formulations for Osteoarthritis Treatments

Osteoarthritis (OA) is the world’s most common degenerative joint disorder, affecting more than 60% of the population over the age of 65.During this condition, bone ...

8 January 2014 Clinical Research V5 I4 | Volume 5 Issue 4

Continue Reading →

Clinical Research V5 I4

A New Future for Antibiotics?

A future without antibiotics is deemed to be bleak, if bacteria continue to develop new resistance mechanisms and the pharmaceutical industry have to produce novel c...

8 January 2014 Clinical Research V5 I4 | Volume 5 Issue 4

Continue Reading →

Clinical Research V5 I4

Screening Kidney Function in People With Carotid Artery Disease May Help In Development Of Early Intervention Strategies

Chronic kidney disease (CKD) is a progressive reduction in the kidneys’ ability to filter blood. People with CKD have greatly increased mortality risk in comparison ...

8 January 2014 Clinical Research V5 I4 | Volume 5 Issue 4

Continue Reading →

Clinical Research V5 I4

Proactive Safety Management for Established Healthcare Products

A recent analysis shows that more than $290 billion of prescription drug sales are at risk from patent expirations between 2011 and 2018. Chitra Lele at Sciformix di...

8 January 2014 Clinical Research V5 I4 | Volume 5 Issue 4

Continue Reading →

Clinical Research V5 I4

Critical Thinking on Criticality

“Critical” is a widely used term in Quality by Design, relating to anything which affects the safety or efficacy of the finished product. Dr. Brian Carlin at FMC Bio...

7 January 2014 Clinical Research V5 I4 | Volume 5 Issue 4

Continue Reading →

Drug Discovery and Development V5 I4

Discovery Toxicology Services

Toxicology the study of poisons, determines whether a drug can be used on humans. Almost 30% of clinical trial attritions are attributed to the toxicological profile...

7 January 2014 Drug Discovery and Development V5 I4 | Volume 5 Issue 4

Continue Reading →

Drug Discovery and Development V5 I4

Improving and Refining Models of Acquired Resistance for Efficient Oncology Drug Discovery

Conventional chemotherapy has been, for many years, the prevalent type of anti-cancer treatment. However its broad-based mechanisms, DNA alkylating agents, usually l...

7 January 2014 Drug Discovery and Development V5 I4 | Volume 5 Issue 4

Continue Reading →

REGULATORY AND MARKETPLACE v5 I4

All Eyes on Austria – Vienna Host of the BIO-Europe Conference for a Second Time in only Four Years

Sonja Polan at Life Science Austria explains how the Austrian biotechnology industry is a true success story, as can be seen from the record number, 116, of innovati...

7 January 2014 REGULATORY AND MARKETPLACE v5 I4 | Volume 5 Issue 4

Continue Reading →